Exelixis

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Phase 12

By Therapeutic Area

top 1

Oncology

2100%

R&D Momentum

52/100

Pipeline Velocity

15/100

Trial Completion Rate

53/100

Pipeline Concentration

100/100

Pipeline Freshness

56/100

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Recruiting

A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Jul 10, 2026

Recruiting

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Earlier

Jun 25, 2026TrialA Phase 1 Dose Escalation and Expansion Study of XB628 as a Single Agent and in Combination With Zanzalintinib in Participants With Advanced or Metastatic Solid Tumors

Jun 24, 2026TrialA Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Jun 24, 2026TrialA Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Aug 18, 2025TrialA Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

May 13, 2025TrialPharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Oct 17, 2024TrialA Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

4 more events

Jun 7, 2024TrialStudy of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Apr 3, 2024TrialA Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Jan 25, 2024TrialStudy of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Jan 1, 2023TrialStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

5 patent groups across drugs · Source: FDA Orange Book

DrugExpires

CometriqAug 14, 2026 Cometriq4 patentsJan 15, 2030 Cometriq2 patentsJul 18, 2031 Cometriq3 patentsFeb 10, 2032 CometriqJul 9, 2033

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Locally Advanced or Metastatic Solid Tumors

XB010

Solid Tumor

XB628

Oncology

Locally Advanced or Metastatic Solid Tumors

XB010Phase 1

Solid Tumor

XB628Phase 1

Regulatory

Regulatory Timeline

20121 event

FDANov 29

Cometriq — COMETRIQ

Application NDA203756 (NDA)

20161 event

FDAApr 25

Cometriq — CABOMETYX

Application NDA208692 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)